Investor Lansdowne Partners Austria Gmbh
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Lansdowne Partners Austria Gmbh . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2016-06-16 13D/A ALXA / Alexza Pharmaceuticals, Inc. 1,739,389 1,733,833
2015-08-03 13D ALXA / Alexza Pharmaceuticals, Inc. 1,739,389
2015-02-17 13G/A ALXA / Alexza Pharmaceuticals, Inc. 1,739,389
2014-07-10 13G/A DATA / Tableau Software, Inc. 0
2014-07-10 13G/A RGDXQ / Response Genetics, Inc 3,805,161
2014-07-10 13G/A CYTK / Cytokinetics, Incorporated 2,848,181
2014-07-10 13G/A MANU / Manchester United plc 2,731,445
2014-02-14 13G/A ALXA / Alexza Pharmaceuticals, Inc. 1,400,811
2013-02-14 13G/A ALXA / Alexza Pharmaceuticals, Inc. 1,690,110
2012-12-31 13G/A ALXA / Alexza Pharmaceuticals, Inc. 1,690,610
2012-12-31 13G ALXA / Alexza Pharmaceuticals, Inc. 1,690,610